
    
      This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the
      effects of brexpiprazole (flexible dose; 0.5 to 2 mg QD) as adjunctive therapy to ADT on life
      engagement in patients with MDD. This trial is being conducted in line with the Canadian
      Product Monograph.
    
  